LivaNova LIVN Cardiopulmonary — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about LivaNova's cardiopulmonary — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is LivaNova's cardiopulmonary — operating income?
- LivaNova (LIVN) reported cardiopulmonary — operating income of $30.07M in Q1 2026.
- How has LivaNova's cardiopulmonary — operating income changed year-over-year?
- LivaNova's cardiopulmonary — operating income increased by 21.8% year-over-year, from $24.69M to $30.07M.
- What is the long-term trend for LivaNova's cardiopulmonary — operating income?
- Over 3 years (2021 to 2025), LivaNova's cardiopulmonary — operating income has grown at a 156.3% compound annual growth rate (CAGR), from -$6.43M to $108.3M.
- What does cardiopulmonary — operating income mean?
- Measures the profitability of the cardiopulmonary segment by subtracting operating expenses, such as cost of sales and SG&A, from net revenue. It reflects the operational efficiency and core earnings power of the segment before interest and taxes.